21Oct 2023
Empagliflozin in patients admitted to hospital with COVID-19

Empagliflozin in patients admitted to hospital with COVID-19

The study assessed empagliflozin's potential as a COVID-19 treatment. Over 4,000 patients were randomly assigned either empagliflozin with standard or standard care alone. Results showed no significant reduction in 28-day mortality (14% in both groups), hospitalization duration (median 8 days for both), or progression to invasive mechanical ventilation or death. This trial's findings provide critical insights into potential COVID-19 therapies and emphasize the need for evidence-based treatments in the fight against the virus.

  • #endo-diabetology

Like

Save

Share